2696 Results for "

A549 treated with fak Inhibitors

" in MedChemExpress (MCE) Product Catalog:
Products (2696)

2696 Results for "A549 treated with fak Inhibitors" in MCE Product Catalog:

1344
1344 Publications Verification
Cat. No.: HY-17589
CAS No.: 50-63-5
Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM) .
loading...
    loading...
1344
1344 Publications Verification
Cat. No.: HY-17589A
CAS No.: 54-05-7
Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM) .
loading...
    loading...
1344
1344 Publications Verification
Cat. No.: HY-17589B
CAS No.: 3545-67-3
Chloroquine dihydrochloride is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine dihydrochloride is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine dihydrochloride is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM) .
loading...
    loading...
147
147 Cited Publications
Cat. No.: HY-12008
CAS No.: 183319-69-9
Purity:  99.94%
Synonyms: CP-358774 hydrochloride; NSC 718781 hydrochloride; OSI-774 hydrochloride
Target:  

EGFR OAT ERK GSK-3 β-catenin

Research Areas:  

Endocrinology Cancer

Erlotinib (CP-358774) Hydrochloride is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib Hydrochloride also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib Hydrochloride blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib Hydrochloride inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, as well as the deposition of fibronectin, α-SMA, collagen and renal injury markers. Erlotinib Hydrochloride is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib Hydrochloride can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, EGFR inhibitor resistance and renal fibrosis .
loading...
    loading...
147
147 Cited Publications
Cat. No.: HY-50896
CAS No.: 183321-74-6
Synonyms: CP-358774; NSC 718781; OSI-774
Target:  

EGFR OAT ERK GSK-3 β-catenin

Research Areas:  

Endocrinology Cancer

Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions .
loading...
    loading...
87
87 Cited Publications
Cat. No.: HY-16562A
CAS No.: 100286-90-6
Synonyms: (+)-Irinotecan hydrochloride; CPT-11 hydrochloride; VAL-413
Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .
loading...
    loading...
72
72 Cited Publications
Cat. No.: HY-10450
CAS No.: 461432-26-8
Purity:  99.97%
Synonyms: BMS-512148
Target:  

SGLT

Research Areas:  

Metabolic Disease Cancer

Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .
loading...
    loading...
72
72 Cited Publications
Cat. No.: HY-10450A
CAS No.: 960404-48-2
Purity:  99.97%
Synonyms: BMS-512148 (2S)-1,2-propanediol, hydrate
Target:  

SGLT

Research Areas:  

Metabolic Disease Cancer

Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury .
loading...
    loading...
71
71 Cited Publications
Cat. No.: HY-10211
CAS No.: 75747-14-7
Purity:  99.01%
Synonyms: 17-AAG; NSC 330507; CP 127374
Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .
loading...
    loading...
64
64 Cited Publications
Cat. No.: HY-12289A
CAS No.: 1073160-26-5
Purity:  99.35%
Synonyms: VS-6063 hydrochloride; PF 04554878 hydrochloride
Target:  

FAK

Research Areas:  

Cancer

Defactinib hydrochloride (VS-6063 hydrochloride; PF 04554878 hydrochloride) is a novel FAK inhibitor, which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.
loading...
    loading...
64
64 Cited Publications
Cat. No.: HY-12289
CAS No.: 1073154-85-4
Purity:  99.87%
Synonyms: VS-6063; PF-04554878
Target:  

FAK

Research Areas:  

Cancer

Defactinib (VS-6063; PF-04554878) is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities.
loading...
    loading...
61
61 Cited Publications
Cat. No.: HY-15162
CAS No.: 474645-27-7
Purity:  99.97%
Synonyms: MMAE; SGD-1010
Research Areas:  

Cancer

Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.
loading...
    loading...
57
57 Cited Publications
Cat. No.: HY-111783
CAS No.: 2230820-11-6
Purity:  99.86%
Research Areas:  

Cancer

AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC50 of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity .
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-15676
CAS No.: 1229705-06-9
Purity:  99.93%
Synonyms: RG7388
Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors .
loading...
    loading...
51
51 Cited Publications
Cat. No.: HY-P0128A
CAS No.: 131602-53-4
Synonyms: Amyloid beta-peptide (25-35), HFIP-treated; Aβ25-35, HFIP-treated; β-Amyloid peptide (25-35), HFIP-treated
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

β-Amyloid (25-35) (Amyloid beta-peptide (25-35)), HFIP-treated is a β-Amyloid (25-35) (HY-P0128) treated with HFIP. β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .
loading...
    loading...
50
50 Cited Publications
Cat. No.: HY-B0099
CAS No.: 89-25-8
Synonyms: MCI-186
Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
loading...
    loading...
50
50 Cited Publications
Cat. No.: HY-W404916
CAS No.: 23795-03-1
Probenecid sodium is an orally active, blood-brain barrier-permeable Pannexin 1 channel inhibitor. Probenecid sodium exhibits anti-inflammatory, antiviral, and neuroprotective activities. Probenecid sodium can be used in research related to multiple sclerosis, focal cerebral ischemic injury, influenza virus infection, and nephropathy .
loading...
    loading...
46
46 Cited Publications
Cat. No.: HY-14644
CAS No.: 541550-19-0
Purity:  99.80%
Synonyms: STA 5326; LAM-002A free base; AIT-101
Research Areas:  

Inflammation/Immunology Cancer

Apilimod (STA 5326) is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively . Apilimod is a potent and highly selective PIKfyve inhibitor.
loading...
    loading...
46
46 Cited Publications
Cat. No.: HY-14644A
CAS No.: 870087-36-8
Purity:  99.83%
Synonyms: STA 5326 mesylate; LAM-002A; AIT-101 mesylate
Research Areas:  

Inflammation/Immunology Cancer

Apilimod (STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively . Apilimod is a potent and highly selective PIKfyve inhibitor.
loading...
    loading...
43
43 Cited Publications
Cat. No.: HY-P0014
CAS No.: 204656-20-2
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
loading...
    loading...